Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Abstract Background The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes...

Полное описание

Библиографические подробности

Главные авторы:	Becky A. S. Bibby, Niluja Thiruthaneeswaran, Lingjian Yang, Ronnie R. Pereira, Elisabet More, Darragh G. McArt, Paul O’Reilly, Robert G. Bristow, Kaye J. Williams, Ananya Choudhury, Catharine M. L. West
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2021-07-01
Серии:	BMC Urology
Online-ссылка:	https://doi.org/10.1186/s12894-021-00856-x
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!